Primer: Administrative health databases in observational studies of drug effects - Advantages and disadvantages

Nature Clinical Practice Rheumatology

Volumn 3, Issue 12, 2007, Pages 725-732

  Suissa, Samy ^a   Garbe, Edeltraut ^b  

^a MCGILL UNIVERSITY   (Canada)

^b UNIVERSITY OF BREMEN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IBUPROFEN; LEFLUNOMIDE; NAPROXEN; NON PRESCRIPTION DRUG; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ACCURACY; ACUTE HEART INFARCTION; ADENOMATOUS POLYP; CANADA; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; DRUG WITHDRAWAL; ELECTRONIC MEDICAL RECORD; FACTUAL DATABASE; HOSPITAL INFORMATION SYSTEM; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MEDICAL INFORMATION SYSTEM; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATIENT INFORMATION; PHARMACY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; PUBLIC HEALTH; REVIEW; RHEUMATOID ARTHRITIS; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; STATISTICAL ANALYSIS; SYSTEMATIC ERROR; THROMBOSIS; TREATMENT DURATION; UNITED STATES;

ANTIRHEUMATIC AGENTS; DATABASES, FACTUAL; DRUG THERAPY; EUROPE; HUMANS; LACTONES; MEDICAL RECORDS; NORTH AMERICA; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RHEUMATIC DISEASES; SULFONES;

EID: 36549071661     PISSN: 17458382     EISSN: 17458390     Source Type: Journal    
DOI: 10.1038/ncprheum0652     Document Type: Review

References (26)

1. Levy M (1974) Aspirin use in patients with major upper gastrointestinal bleeding and peptic-ulcer disease. A report from the Boston Collaborative Drug Surveillance Program, Boston University Medical Center. N Engl J Med 290:1158-1162
2. Carson JL et al. (1987) The association of nonsteroidal anti-inflammatory drugs with upper gastrointestinal tract bleeding. Arch Intern Med 147: 85-88
3. Strom BL (2005) Pharmacoepidemiology, edn 4. Chichester: John Wiley & Sons Ltd
4. Strom BL et al. (1991) Using a claims database to investigate drug-induced Stevens-Johnson syndrome. Stat Med 10: 565-576
5. Spitzer WO et al. (1992) The use of beta-agonists and the risk of death and near death from asthma. N Engl J Med 326: 501-506
6. Suissa S et al. (1994) Patterns of increasing beta-agonist use and the risk of fatal or near-fatal asthma. Eur Respir J 7: 1602-1609
7. Strom BL and Carson JL (1990) Use of automated databases for pharmacoepidemiology research. Epidemiol Rev 12: 87-107
8. Ray WA and Griffin MR (1989) Use of medicaid data for pharmacoepidemiology. Am J Epidemiol 129: 837-849
9. Downey W et al. (2005) Health databases in Saskatchewan. In Pharmacoepidemiology, edn 4 295-310 (Ed Strom BL) Chicester: John Wiley & Sons Ltd
10. Selby JV et al. (2005) Kaiser Permanente Medical Care Program. In Pharmacoepidemiology, edn 4 261-270 (Ed Strom BL) Chichester: John Wiley & Sons Ltd
11. Saunders KW et al. (2005) Group Health Cooperative. In Pharmacoepidemiology, edn 4 223-240 (Ed Strom BL) Chichester: John Wiley & Sons Ltd
12. Solomon SD et al. (2005) Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 352: 1071-1080
13. Bombardier C et al. (2000) Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group. N Engl J Med 343: 1520-1528
14. Ray WA et al. (2002) COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet 360: 1071-1073
15. Mamdani M et al. (2003) Effect of selective cyclooxygenase 2 inhibitors and naproxen on shortterm risk of acute myocardial infarction in the elderly. Arch Intern Med 163: 481-486
16. Solomon DH et al. (2004) Relationship between selective cyclooxygenase-2 inhibitors and acute myocardial infarction in older adults. Circulation 109: 2068-2073
17. FDA Advisory Committee, U.S. Food and Drug Administration (online 9 December 2004) Cardiovascular safety review of rofecoxib [http://www.fda.gov/ohrms/dockets/ac/01/briefing/3677b1_11thrombo.doc] (accessed 20 September 2007)
18. Suissa S (2007) Immortal time bias in observational studies of drug effects. Pharmacoepidemiol Drug Saf 16: 241-249
19. Mamdani M et al. (2002) Observational study of upper gastrointestinal haemorrhage in elderly patients given selective cyclo-oxygenase-2 inhibitors or conventional non-steroidal anti-inflammatory drugs. BMJ 325: 624
20. Ray WA (2003) Evaluating medication effects outside of clinical trials: new-user designs. Am J Epidemiol 158: 915-920
21. McGettigan P and Henry D (2006) Cardiovascular risk and inhibition of cyclooxygenase: A systematic review of the observational studies of selective and nonselective inhibitors of cyclooxygenase 2. JAMA 296: 1633-1644
22. Andersohn F et al. (2006) Use of first- and second-generation cyclooxygenase-2-selective nonsteroidal anti-inflammatory drugs and risk of acute myocardial infarction. Circulation 113: 1950-1957
23. Suissa S et al. (2004) Newer disease modifying antirheumatic drugs (DMARDS) and the risk of serious hepatic adverse events in rheumatoid arthritis. Am J Med 117: 87-92
24. Brassard P et al. (2006) Antirheumatic drugs and the risk of tuberculosis. Clin Infect Dis 43: 717-722
25. Bematsky S et al. (2005) Anti-rheumatic drug use and risk of hospitalization for congestive heart failure in rheumatoid arthritis. Rheumatology (Oxford) 44: 677-680
26. Suissa S et al. (2006) Antirheumatic drug use and the risk of acute myocardial infarction. Arthritis Rheum 55: 531-536